Relatlimab-Nivolumab Ups PFS in Untreated Advanced Melanoma
Combination provides greater benefit than nivolumab alone for progression-free survival in untreated metastatic or unresectable melanoma
Melanoma And Other Skin Cancers
Keytruda Approved for Adjuvant Treatment IIB, IIC Melanoma Following Resection
Approval was based on data from the phase 3 KEYNOTE-716 trial, which enrolled 976 participants.
Giving Nivolumab/Ipilimumab First Ups Overall Survival in Melanoma
Two-year overall survival 72 percent for those starting with N/I, 52 percent for those starting with dabrafenib/trametinib
Relatlimab-Nivolumab Fixed-Dose Combo Gets Priority Review for Melanoma
The application is supported by data from the phase 2/3 RELATIVITY-047 trial.
Some Cancer Drugs Without Proven Benefit Still Recommended
Six of 18 indications remain on label for cancer drugs that failed to improve primary end point in trials after receiving accelerated approval
Nemvaleukin Alfa Fast Tracked for Mucosal Melanoma
Nemvaleukin alfa is an investigational, engineered fusion protein consisting of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.
Keytruda Approved for Locally Advanced Cutaneous Squamous Cell Carcinoma
Results showed an overall response rate of 50%, with 17% of patients achieving complete response and 33% having partial response.
Lymphoseek Approval Expanded to Pediatric Patients
The approval was based on data from a phase 2 trial that assessed Lymphoseek in pediatric patients with melanoma, RMS, or other solid tumors.
Changes in Cancer Incidence, Deaths Expected by 2040
Most common cancers will be breast, melanoma, and lung, while most common cause of cancer-related death will remain lung
Cavrotolimod Designated Orphan Drug for Merkel Cell Carcinoma
Cavrotolimod is a toll-like receptor 9 agonist that is designed to induce anticancer immune responses through proprietary spherical nucleic acid (SNA™) technology.
